INT118291

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.10
First Reported 2001
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 19
Total Number 19
Disease Relevance 11.77
Pain Relevance 1.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (TXK) nucleus (TXK) DNA binding (TXK)
cytoplasm (TXK)
Anatomy Link Frequency
endothelial cells 1
extracellular matrix 1
epithelial cell 1
lung 1
TXK (Homo sapiens)
Pain Link Frequency Relevance Heat
Nerve growth factor 26 99.68 Very High Very High Very High
lidocaine 5 93.52 High High
rheumatoid arthritis 83 87.92 High High
cytokine 33 83.72 Quite High
Pain 98 83.16 Quite High
Osteoarthritis 48 82.40 Quite High
Chronic pancreatitis 4 79.60 Quite High
Analgesic 7 79.48 Quite High
metalloproteinase 1 76.56 Quite High
cva 18 72.08 Quite High
Disease Link Frequency Relevance Heat
Breast Cancer 377 99.48 Very High Very High Very High
Disease 157 98.56 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 170 97.96 Very High Very High Very High
Ovarian Cancer 59 97.92 Very High Very High Very High
Cancer 521 97.76 Very High Very High Very High
Lung Cancer 16 97.44 Very High Very High Very High
Myeloid Leukemia 28 96.12 Very High Very High Very High
Repression 2 95.36 Very High Very High Very High
Chronic Myeloid Leukemia 7 94.40 High High
Pancreatic Cancer 59 94.00 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Imatinib's effect is mediated by its ability to bind to the ATP-binding site on the tyrosine kinase, thus preventing its function.
tyrosine kinase Binding (bind) of
1) Confidence 0.10 Published 2009 Journal World J Surg Oncol Section Body Doc Link PMC2661077 Disease Relevance 0.89 Pain Relevance 0.05
Epidermal growth factor receptor (EGFR), a tyrosine kinase receptor with an important role in epithelial cell proliferation after corneal wounding, also possesses these amino acids sequences around autophosphorylation sites.
tyrosine kinase Binding (possesses) of in epithelial cell
2) Confidence 0.10 Published 2004 Journal Anesthesiology Section Abstract Doc Link 15114219 Disease Relevance 0.08 Pain Relevance 0.50
subtypes [6], and multiple regulatory interactions between steroid hormone, growth factor, and other tyrosine kinase signaling pathways [7–10].
tyrosine kinase Binding (interactions) of
3) Confidence 0.09 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001220 Disease Relevance 0.45 Pain Relevance 0
some of the steric hindrances normally imposed on the tyrosine kinase activity,
tyrosine kinase Binding (activity) of
4) Confidence 0.06 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.14 Pain Relevance 0
interact with second messengers like calmodulin [10].

(3) Tyrosine Kinase DomainThe tyrosine kinase domain (TKD) is essential for the functional

tyrosine kinase Binding (interact) of
5) Confidence 0.06 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0 Pain Relevance 0
PF-00299804 is an orally active pan-HER tyrosine kinase inhibitor which specifically and irreversibly binds to and inhibits HER1, HER2 and HER4 which was evaluated in non-small cell lung cancer patients at ASCO 2008 but also exhibits potential activity in HER2 positive breast cancer patients.[67]
tyrosine kinase Binding (binds) of in lung associated with lung cancer and breast cancer
6) Confidence 0.06 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 1.06 Pain Relevance 0.06
interact with second messengers like calmodulin [10].

(3) Tyrosine Kinase DomainThe tyrosine kinase domain (TKD) is essential for the functional

Tyrosine Kinase Binding (interact) of
7) Confidence 0.06 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0 Pain Relevance 0
Lapatinib binds to the ATP-binding site of tyrosine kinase, blocking phosphorylation and activation of the receptor.
tyrosine kinase Binding (binds) of
8) Confidence 0.05 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727787 Disease Relevance 0.48 Pain Relevance 0
Among EGF-R-targeting therapies, there are two large categories of molecules: monoclonal antibodies, which recognize the ligand-binding domain and interfere with receptor activation, and tyrosine kinase inhibitors which bind to the cytoplasmatic region and influence with downstream signalling events.
tyrosine kinase Binding (bind) of
9) Confidence 0.04 Published 2010 Journal Head Neck Oncol Section Body Doc Link PMC2868849 Disease Relevance 0.78 Pain Relevance 0
TKIs bind intracellularly to EGF-R tyrosine-kinase and block downstream signalling pathways.
tyrosine-kinase Binding (bind) of
10) Confidence 0.03 Published 2010 Journal Head Neck Oncol Section Body Doc Link PMC2868849 Disease Relevance 0.23 Pain Relevance 0.05
This peptide has an effect on endothelial cells by interacting with heparan-sulfate proteoglycans and tyrosine kinase FGF receptors.
tyrosine kinase Binding (interacting) of in endothelial cells
11) Confidence 0.03 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895781 Disease Relevance 1.52 Pain Relevance 0.06
The first of these disease-tailored products has been imatinib mesylate (IM) which blocks the ATP-binding pocket on the BCR-ABL tyrosine-kinase and thus prevents the activation of this enzyme which plays the key role in the pathogenesis of CML [13].
tyrosine-kinase Binding (binding) of associated with myeloid leukemia and disease
12) Confidence 0.03 Published 2010 Journal Clinical and Developmental Immunology Section Body Doc Link PMC3004381 Disease Relevance 1.18 Pain Relevance 0.04
The inhibition of tyrosine kinase activity by 5 ?
tyrosine kinase Binding (activity) of
13) Confidence 0.02 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC400678 Disease Relevance 0.48 Pain Relevance 0
ETV1, SP4, cAMP-response element binding protein); signal-transduction molecules (e.g. the catalytic subunit of phospatidylinositol 3-kinase-gamma, protein-tyrosine phosphatase-zeta, human tyrosine kinase and its receptor); and molecules involved in matrix formation and cell-extracellular matrix contact (e.g. the ?
tyrosine kinase Binding (receptor) of in extracellular matrix
14) Confidence 0.02 Published 2001 Journal Arthritis Res Section Body Doc Link PMC64845 Disease Relevance 0.55 Pain Relevance 0.21
Each NT binds with high affinity to a receptor tyrosine kinase (Trk): NGF to TrkA, BDNF and NT4/5 to TrkB and NT3 to TrkC.
tyrosine kinase Binding (binds) of associated with nerve growth factor
15) Confidence 0.02 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206352 Disease Relevance 1.16 Pain Relevance 0.87
HER2 has also been shown to communicate with VEGFR, and studies in breast cancer have shown a synergistic interaction with the combination of trastuzumab and a VEGFR tyrosine kinase inhibitor [97].
tyrosine kinase Binding (interaction) of associated with breast cancer
16) Confidence 0.01 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.61 Pain Relevance 0
K-ras is a guanyl-nucleotide binding protein with GTPase activity that mediates intracellular signaltransduction of growth factors that bind to tyrosine-kinase receptors.
tyrosine-kinase Binding (bind) of
17) Confidence 0.01 Published 2003 Journal Mol Cancer Section Body Doc Link PMC149419 Disease Relevance 1.01 Pain Relevance 0.08
Gefitinib is a small molecule tyrosine kinase inhibitor that binds to the ATP-binding site of the EGF receptor and thereby prevents its activation.
tyrosine kinase Binding (binds) of
18) Confidence 0.01 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2814233 Disease Relevance 0.56 Pain Relevance 0
We investigated the impact of tumor vascular endothelial growth factor A (VEGF-A) expression on the efficacy of LD paclitaxel chemotherapy and its interactions with the tyrosine kinase inhibitor SU5416 in the ID8 and ID8-Vegf models of ovarian cancer.
tyrosine kinase Binding (interactions) of associated with cancer and ovarian cancer
19) Confidence 0.00 Published 2008 Journal J Transl Med Section Abstract Doc Link PMC2235830 Disease Relevance 0.59 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox